On a cool morning last November, 800 people gathered before sunrise in a South Burlington hangar to witness the maiden flight of Beta Technologies’ first ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...
“Boy, his hat is crises!” said Bob Dudley, former BP CEO and a mentor to Auchincloss. “I always said to Murray: management ...
Exelixis, Inc. today announced that the company's Board of Directors has authorized the repurchase of up to an additional $500 million of the company's common stock before December 31, 2025. Exelixis ...
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target of ...